Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.

PubWeight™: 1.22‹?› | Rank: Top 10%

🔗 View Article (PMID 12473576)

Published in Clin Cancer Res on December 01, 2002

Authors

Andreas M Kaufmann1, Peter L Stern, Elaine M Rankin, Harald Sommer, Volkmar Nuessler, Achim Schneider, Malcom Adams, Toli S Onon, Thomas Bauknecht, Uwe Wagner, Karlijn Kroon, Julian Hickling, Christopher M Boswell, Simon N Stacey, Henry C Kitchener, Jennifer Gillard, Jantien Wanders, John St C Roberts, Heinz Zwierzina

Author Affiliations

1: Frauenklinik, Friedrich-Schiller-University of Jena, 07743 Jena, Germany. a.kaufmann@med.uni-jena.de

Articles citing this

Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med (2012) 1.84

Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract. Clin Cancer Res (2015) 1.47

Therapeutic human papillomavirus vaccines: current clinical trials and future directions. Expert Opin Biol Ther (2008) 1.24

Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci Transl Med (2014) 1.21

Synthetic DNA vaccines: improved vaccine potency by electroporation and co-delivered genetic adjuvants. Front Immunol (2013) 1.19

Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs (2010) 1.18

HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein. J Virol (2006) 1.15

Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients. J Cancer Res Clin Oncol (2003) 1.10

A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers. J Biol Chem (2010) 1.00

Perspectives for preventive and therapeutic HPV vaccines. J Formos Med Assoc (2010) 0.99

Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol Rev (2008) 0.96

Immunologic treatments for precancerous lesions and uterine cervical cancer. J Exp Clin Cancer Res (2014) 0.96

Emerging human papillomavirus vaccines. Expert Opin Emerg Drugs (2012) 0.96

Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects. Cancer Immunol Immunother (2013) 0.94

Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res (2013) 0.92

Human papillomaviruses as therapeutic targets in human cancer. J Clin Oncol (2011) 0.90

Therapeutic Vaccine Strategies against Human Papillomavirus. Vaccines (Basel) (2014) 0.89

Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination. J Biomed Sci (2010) 0.89

The future of vaccines for cervical cancer. Gynecol Oncol (2008) 0.87

Immunogenicity of bivalent human papillomavirus DNA vaccine using human endogenous retrovirus envelope-coated baculoviral vectors in mice and pigs. PLoS One (2012) 0.86

Therapeutic vaccines against human papillomavirus and cervical cancer. Open Virol J (2009) 0.85

Single-dose, therapeutic vaccination of mice with vesicular stomatitis virus expressing human papillomavirus type 16 E7 protein. Clin Vaccine Immunol (2008) 0.85

Perspectives for therapeutic HPV vaccine development. J Biomed Sci (2016) 0.85

Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research. J Gynecol Oncol (2016) 0.83

Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studies. Expert Rev Vaccines (2016) 0.82

Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine. Hum Gene Ther (2014) 0.81

Progress and challenges in the vaccine-based treatment of head and neck cancers. J Exp Clin Cancer Res (2009) 0.81

Immunogenicity of a trivalent human papillomavirus L1 DNA-encapsidated, non-replicable baculovirus nanovaccine. PLoS One (2014) 0.81

Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial. ISRN Obstet Gynecol (2011) 0.81

Viruses and human cancer. Yale J Biol Med (2006) 0.80

Design of a highly effective therapeutic HPV16 E6/E7-specific DNA vaccine: optimization by different ways of sequence rearrangements (shuffling). PLoS One (2014) 0.78

Progress in the development of a cervical cancer vaccine. Ther Clin Risk Manag (2006) 0.78

Potent anti-tumor effect generated by a novel human papillomavirus (HPV) antagonist peptide reactivating the pRb/E2F pathway. PLoS One (2011) 0.77

Perspective for prophylaxis and treatment of cervical cancer: an immunological approach. Int Rev Immunol (2012) 0.77

Screening of drugs to counteract human papillomavirus 16 E6 repression of E-cadherin expression. Invest New Drugs (2012) 0.77

Mutagenic Potential ofBos taurus Papillomavirus Type 1 E6 Recombinant Protein: First Description. Biomed Res Int (2015) 0.75

Immunotherapy: New Strategies for the Treatment of Gynecologic Malignancies. Oncology (Williston Park) (2016) 0.75

The current state of therapeutic and T cell-based vaccines against human papillomaviruses. Virus Res (2016) 0.75

Articles by these authors

Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007) 19.18

Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet (2007) 12.65

Genetic determinants of hair, eye and skin pigmentation in Europeans. Nat Genet (2007) 8.79

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet (2007) 8.55

Parental origin of sequence variants associated with complex diseases. Nature (2009) 7.21

Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat Genet (2009) 6.91

Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. Nat Genet (2008) 6.69

Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10

Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet (2009) 5.06

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol (2006) 4.92

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet (2011) 4.73

ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet (2008) 3.90

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst (2003) 3.77

Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol (2008) 3.75

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol (2010) 3.46

Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nat Genet (2009) 3.46

Two newly identified genetic determinants of pigmentation in Europeans. Nat Genet (2008) 3.31

Future acceptance of adolescent human papillomavirus vaccination: a survey of parental attitudes. Vaccine (2006) 3.18

Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet (2011) 3.06

Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88

A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res (2002) 2.86

Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med (2010) 2.83

The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer (2005) 2.74

Genome-wide association study identifies sequence variants on 6q21 associated with age at menarche. Nat Genet (2009) 2.58

A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet (2010) 2.56

Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol (2004) 2.50

Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32

Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression. Genes Chromosomes Cancer (2008) 2.29

A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. Nat Genet (2012) 2.29

Meta-analyses identify 13 loci associated with age at menopause and highlight DNA repair and immune pathways. Nat Genet (2012) 2.12

Epithelial-mesenchymal transition events during human embryonic stem cell differentiation. Cancer Res (2007) 2.10

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol (2010) 2.03

Clinical relevance of objectifying colposcopy. Arch Gynecol Obstet (2014) 2.03

Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol (2011) 1.95

Evaluation of the VITOM in digital high-definition video exocolposcopy. J Low Genit Tract Dis (2011) 1.87

Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst (2006) 1.86

Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res (2008) 1.83

Discovery of common variants associated with low TSH levels and thyroid cancer risk. Nat Genet (2012) 1.81

Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene (2005) 1.80

A new approach to preserve fertility by using a coated nitinol stent in a patient with recurrent cervical stenosis. Fertil Steril (2006) 1.78

A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med (2008) 1.77

Multicenter validation study of the sentinel lymph node concept in cervical cancer: AGO Study Group. J Clin Oncol (2008) 1.77

Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev (2010) 1.75

A polymorphism in IRF4 affects human pigmentation through a tyrosinase-dependent MITF/TFAP2A pathway. Cell (2013) 1.75

Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol Cancer (2003) 1.73

Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol (2005) 1.70

Laparoscopic-assisted radical vaginal hysterectomy (LARVH): prospective evaluation of 200 patients with cervical cancer. Gynecol Oncol (2003) 1.70

Preventive therapy for breast cancer: a consensus statement. Lancet Oncol (2011) 1.69

Analysis of morbidity in patients with endometrial cancer: is there a commitment to offer laparoscopy? Gynecol Oncol (2005) 1.68

Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst (2012) 1.68

Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation. Genome Med (2012) 1.65

Solid neuroendocrine carcinomas of the breast: metastases or primary tumors? Breast Cancer Res Treat (2010) 1.63

European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum Mol Genet (2011) 1.58

Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. J Clin Oncol (2008) 1.57

Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study. Clin Cancer Res (2007) 1.57

Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis. Clin Cancer Res (2011) 1.56

Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer. Cancer Res (2004) 1.53

Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst (2002) 1.52

Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin Cancer Res (2004) 1.51

Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes. Genes Chromosomes Cancer (2007) 1.50

The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother (2005) 1.50

New paradigm for prevention of cervical cancer. Eur J Obstet Gynecol Reprod Biol (2006) 1.48

HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol (2009) 1.48

Human papillomavirus and cervical cancer. Lancet (2013) 1.48

TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst (2004) 1.45

An in vivo and in vitro model of Plasmodium falciparum rosetting and autoagglutination mediated by varO, a group A var gene encoding a frequent serotype. Infect Immun (2008) 1.45

A semi-qualitative study of attitudes to vaccinating adolescents against human papillomavirus without parental consent. BMC Public Health (2007) 1.44

Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression. Mol Cancer (2006) 1.44

Laparoscopic pelvic lymphadenectomy in 32 pregnant patients with cervical cancer: rationale, description of the technique, and outcome. Int J Gynecol Cancer (2014) 1.41

Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Clin Breast Cancer (2010) 1.41

Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma. BMC Cancer (2004) 1.40

Cyclodimerization of an oxoboryl complex induced by trans ligand abstraction. Angew Chem Int Ed Engl (2010) 1.39

Bead-isolated human CD4+CD25+ T regulatory cells are anergic and significantly suppress proliferation of CD4+CD25- T responder cells. Clin Immunol (2006) 1.38

Informing adolescents about human papillomavirus vaccination: what will parents allow? Vaccine (2008) 1.37

Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine (2008) 1.35

Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer (2005) 1.35

Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. J Clin Oncol (2006) 1.34

The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer. PLoS Genet (2012) 1.33

Laparoscopy versus laparotomy in endometrial cancer: first analysis of survival of a randomized prospective study. J Minim Invasive Gynecol (2005) 1.32

Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother (2007) 1.32

The majority of viral-cellular fusion transcripts in cervical carcinomas cotranscribe cellular sequences of known or predicted genes. Cancer Res (2008) 1.30

Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha. Mol Cancer (2008) 1.29

Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients. J Pharmacokinet Pharmacodyn (2003) 1.28

Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int J Cancer (2013) 1.27

Differentiation of phyllodes breast tumors from fibroadenomas on MRI. AJR Am J Roentgenol (2005) 1.27

Radical vaginal trachelectomy (RVT) combined with laparoscopic pelvic lymphadenectomy: prospective multicenter study of 100 patients with early cervical cancer. Gynecol Oncol (2006) 1.26

E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cells. Mol Biol Cell (2007) 1.26

Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies. J Clin Oncol (2009) 1.26

Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus species. Cancer Res (2006) 1.26

Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res (2003) 1.24

Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res (2006) 1.24

Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group. J Clin Oncol (2008) 1.19

Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res (2010) 1.18

A variant in FTO shows association with melanoma risk not due to BMI. Nat Genet (2013) 1.17